Allergan switches to all-cash for Kythera buy; Endo sheds 'non-core' portfolio;

@FiercePharma: Lilly faces first trial over claims of Cymbalta withdrawal symptoms. Report | Follow @FiercePharma

@EricPFierce: FDA may add Baxter saline Mexico plant to U.S. supply. Now if Baxter can just quit having to recall saline. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: DME data helps Eylea soar in Q2--and poach market share from its Roche rivals. Article | Follow @CarlyHFierce

> Allergan ($AGN) said its pending buyout of Kythera Biopharmaceuticals ($KYTH) will now be an all-cash deal rather than an 80/20 cash and stock transaction. Release

> Endo ($ENDP) hived off a portfolio of device, vaccine and other "non-core" products from its South Africa-based subsidiary to an investment consortium, aiming to zero in further on specialty meds. Release

> Mallinckrodt ($MNK) saw its second-quarter profits soar as its specialty drug sales racked up gains from recent dealmaking, but overall sales fell short of analyst expectations on slowing Acthar growth. Report

> AMAG Pharmaceuticals ($AMAG) said it would sell $450 million in notes due 2023 to help finance its buyout of Cord Blood Registry. Release

> Orexo said its opioid addiction drug Zubsolv lost its spot on CVS Health's ($CVS) 2016 standard formulary. Release

Medical Device News

@FierceMedDev: Mevion moves on from IPO to up to $200M JV backed by China, U.S. investors. Article | Follow @FierceMedDev

@StacyALawrence: Boston Sci ups cardiac monitoring, partners with wearable patch startup Preventice. Story | Follow @StacyALawrence

@VarunSaxena2: IYCMI: Citing cybersecurity concerns, FDA says not to use Hospira infusion pump. Article | Follow @VarunSaxena2

@EmilyWFierce: FDA doubles down on duodenoscope safety with list of cleaning recs. Report | Follow @EmilyWFierce

> Israeli biotech gets $27M to back pivotal trial of gelatin-based GI surgical sealant. News

> Med tech megamergers haven't translated to massive layoffs--at least not yet. Editor's corner

Biotech News

@FierceBiotech: Baxalta to Shire: The answer is still 'no.' Article | Follow @FierceBiotech

@JohnCFierce: Mystery solved: Star biotech team rallies behind a $36M diabetes spinout from Salk. Article | Follow @JohnCFierce

@DamianFierce: "IPO (n.): An acronym for 'initial public offering' that neglects to mention the taking." More | Follow @DamianFierce

> Cannabis patch startup plots a $42M IPO to fund drugs for epilepsy, pain. Story

> Judge orders a halt to Alzheimer's spat as Eli Lilly chooses sides in dispute. Article

> Intec Pharma stumbles to $30M IPO as Parkinson's program fails to excite investors. More

Biotech Research News

> Study IDs a new pathway for drug research into calorie-burning brown fat. Report

> Scripps team finds a drug that fights addiction by eliminating memories. More

> BU researchers identify a new, more precise target for breast cancer. Story

> Virus-like nanoparticle vaccine used to guard against RSV. Item

> Uppsala University points to anti-inflammatory IL-35 as beneficial in pre-clinical Type 1 diabetes. Article

Diagnostics News

> UC Berkeley researchers create faster form of DNA amplification using LED lighting. Article

> NIH study finds blood biomarker for traumatic brain injury using sensitive analyzer. Story

> Foundation Medicine trips in Q2 with sluggish test reimbursement. More

> OraSure gets FDA nod for emergency use of rapid Ebola test. Report

> Illumina sends off first three companies from genomics startup incubator. Article

Pharma Marketing News

> Allergan taps purple-haired millennial mascot for hashtag-heavy women's health push. Story

> CVS creates one-on-one diabetes rivalries with new formulary exclusions. Report

> Pharma leaves ad agencies behind for in-house digital marketing teams. More

> Pfizer nabs rights to Copaxone copycats, setting up head-to-head generics fight with Novartis. Story

> Slam dunk: Novo Nordisk re-signs NBA Hall of Famer for Victoza marketing. Article

And Finally ... Drugmakers may need to redefine their notions about market access to maximize growth in emerging markets. Report

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.